Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393632 | 0.84 | EPHX2 (0.45) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL287559 | 0.82 | SIGMAR1 (0.49) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL6567915 | 0.82 | LMNA (0.47) | — | |
| SCHEMBL60979 | 0.81 | CTSS (0.54) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL705394 | 0.79 | CTSS (0.56) | OPRM1OPRD1OPRK1CTSSCTSK | |
| SCHEMBL2440428 | 0.78 | SLC18A3 (0.60) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL7419921 | 0.78 | SLC18A3 (0.60) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL9133642 | 0.78 | SLC18A3 (0.60) | SIGMAR1EPHX2OPRM1OPRD1OPRK1 | |
| SCHEMBL6877800 | 0.77 | CYP1A2 (0.46) | SIGMAR1 | |
| SCHEMBL205556 | 0.77 | ALDH1A1 (0.52) | SIGMAR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |